LANSING, Mich., –April 30^th, 2015 – Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of advanced spider silk based fibers, announced today that it has retained the New York law firm of Hunter Taubman Fischer LLC as legal counsel for all securities related matters.

“We are happy to announce that Hunter Taubman Fischer LLC will be representing the Company for SEC filings, compliance and general securities related matters” said Company founder and CEO Kim Thompson.  “We are very pleased to be in a position to make this appointment as we strengthen our management support team.  Hunter Taubman Fischer LLC has a proven track record for supporting a growing business such as ours.  We believe that the addition of Hunter Taubman Fischer LLC to the Kraig labs team will help improve our communications with both regulators and the investment community.   This move is a planned component of our future growth plans.  Their reputation for delivering outstanding client support in the areas of securities law and mergers & acquisitions was a key element of our decision.  We look forward to working with them as we institute our plans to expand Kraig Labs operations.”

The law firm of Hunter Taubman Fischer LLC (HTF) possess a broad base of knowledge and extensive experience in the areas of securities and mergers & acquisitions.  As a result of the global nature of HTF’s practice, they have attorneys fluent in English, Spanish, Portuguese, Mandarin and Cantonese.  They serve a wide range of public companies, focused on growth, trading on the NASDAQ, and NYSE. HTF will serve as the primary interface for Kraig Labs SEC communications and filings, with the goal of improving both the speed and effectiveness of all future filings.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies. The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass.

These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC.

(720) 288-8495

ir@KraigLabs.com

Kraig Labs strengthens management team, appointing new Chief Operations Officer with strong product development and commercialization experience

LANSING, Mich., –January 21, 2015 – Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of advanced spider silk based fibers, announces Jon Rice as the new Chief Operations Officer effective immediately.    Jon joins Kraig from Ultra Electronics (AMI) where he was responsible for all new product development and commercialization.  While at Ultra, Jon lead the development of advanced technologies for the US and global defense markets. In his new role he will provide direction for the commercialization of Kraig labs technologies including MonsterSilk^TM.

“Kraig Labs’ spider silk technology is the perfect fit for my passion and background in transitioning powerful, disruptive technologies.  Spider Silk is a product with tremendous potential and I’m honored to join a team so dedicated to seeing that vision realized.  The opportunity to be a part of the commercialization of this technology was an opportunity I could not pass up,” said Rice.

As COO Jon will be reporting directly to the Company CEO, Kim Thompson.  “We are excited that the Company has reached the point in its growth that it can bring in someone of Jon’s caliber.  He brings a proven track record of successfully transitioning products from development through to viable commercial products.  Jon will play an instrumental role in scaling up our production capacity and leading the growth of Kraig Labs.  We recruited Jon after an extensive search for a candidate we believed could make a real difference in our efforts to bring our products to market.  As part of our search we reviewed more than 1200 resumes from candidates coming out of the nation’s top MBA schools.  Jon was chosen because of his stellar track record, his experience in product development and commercialization, and his keen intellect and business drive.  His unique blend of business and technical acumen make him a great addition to our team,” Thompson concluded.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies. The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC.

(720) 288-8495

ir@KraigLabs.com

Internationale Textilmaschinen Ausstellung recognizes Kraig in “Most innovative small company” and “Best innovation – Agrotextiles” Classifications

LANSING, Mich., — Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of advanced spider silk based fibers, announced today that the Company was named finalist in two categories for Internationale Textilmaschinen Ausstellung’s (“ITMA”) Future Materials Awards 2014.

“I would like to thank ITMA, the world’s largest international textile machinery exhibition, for recognizing our technology and efforts, and congratulate the other finalists for making the shortlist.  I believe that the recognition in the ‘Most innovative small company’ and ‘Best innovation, Agrotextiles’ categories is a testament to our team, our technology and our shareholders,” said Kraig CEO and founder, Kim K. Thompson.

Further ITMA Future Materials Awards 2014 information can be viewed at the following link: www.futurematerialsawards.com

Finalists can be viewed at the following link: www.futurematerialsawards.com/finalists.html

Further ITMA information can be viewed at the following link: www.cematex.com/whatisitma.cfm

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies. The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC.

(720) 288-8495

ir@KraigLabs.com

MonsterSilk™ featured in Textile World edition to be distributed to all Innovation Forum 2014 Attendees

LANSING, Mich., — Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of advanced spider silk based fibers, announced today that the Company’s MonsterSilk™ fiber commercialization ramp up program is the subject of a current article in Textile World.

“It is a huge honor to be featured in this month’s publication of Textile World,” said Kraig CEO and founder, Kim K. Thompson.

“We appreciate the industry exposure for genetically engineered spider silk.  As reported, we are working diligently to expand production and bring our product to commercialization.  Toward that end, our plan is to both expand our production into additional facilities and increase our fiber production at current facilities,” concluded Thompson.

The article can be viewed at the following link; http://www.textileworld.com/Issues/2014/September_October/Quality_Fabric_Of_The_Month/Guided_By_The_Silk.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies. The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC.

(720) 288-8495

ir@KraigLabs.com

New Testing Advancements to Improve Spider Silk Material Quality and Reduce Variability

LANSING, Mich., –July 30, 2014- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of advanced spider silk based fibers, announces that research scientists who are working as consultants for the Company have recently implemented a new materials analysis protocol to further improve the quality of the Company’s genetically engineered spider silk based fibers.

The scientists tested the new procedures and are now using them to test individual fiber filaments.  The innovation allows Kraig to gather testing data on its transgenics even before the transgenics reach the stage where they are spinning cocoons.  This early testing data is then incorporated into the decision making process, regarding artificial selection and selective breeding. The new process means the research team can assess, and then make adjustments to variations in, the silk colony, reduce variability, and, the Company believes, further increase the quality of its recombinant fiber production.

“One of the biggest issues we have faced, as we focus on moving our materials to market, is natural variability between individual fiber filaments.  This new protocol and procedure is a significant breakthrough that will allow us to improve quality, while reducing variability. Overcoming this major hurdle has a direct impact in the laboratory and the commercial ramp up program,” said Company founder and CEO, Kim K. Thompson. “I want to thank the scientists who have implemented and are perfecting this protocol, which we believe will have a real impact on our commercialization program.” Thompson concluded.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies. The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC.

(720) 288-8495

ir@KraigLabs.com

LANSING, Mich., July 15, 2014– Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of advanced spider silk based fibers, announces today that “Monster Silk®” is now a registered trademark with the U.S. Patent and Trademark Office.  Monster Silk®, a genetically engineered spider silk fiber, is in the early stages of commercialization.

In addition to Monster Silk®, the U.S. Patent and Trademark Office has registered the Company’s Spiderpillar® and Spilk® trademarks.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies. The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC.

(720) 288-8495

ir@KraigLabs.com

Kraig Achieves another Milestone in Spider Silk Commercialization

LANSING, Mich., July 9, 2014— Kraig Biocraft Laboratories, Inc. (OTCQB:KBLB) (“Company”), the leading developer of advanced spider silk based fibers, announced that its Monster Silk™ production program has successfully doubled in size, achieving another major milestone in the Company’s spider silk commercialization process.

“Earlier this year, we set ambitious goals for the growth of our Company and for the production of genetically engineered spider silk,” said Company Founder and CEO, Kim K Thompson “Since then, we have expanded our productive capacity in order to make that growth a reality. The current production run is by far the largest in the Company’s history. The doubling of production is an important milestone in the commercialization of spider silk and is affirmation of the success of our production plan and commercialization strategy,” stated Thompson.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies. The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC.

(720) 288-8495

ir@KraigLabs.com

Spider Silk Textile Development Breakthrough

LANSING, Mich., June 18, 2014– Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Kraig”), the leading developer of advanced spider silk based fibers, announced today Warwick Mills (“Warwick”), a leader in the engineering and development of advanced technical textiles and protective materials, created the world’s first textile utilizing Kraig’s genetically engineered spider silk, Monster Silk™.

The first Monster Silk™ textiles are knitted gloves and the first photos are available at the following link- https://www.kraiglabs.com/spider-silk-textiles/.  They are considered to be the first of many textiles that are to be created as part of the Company’s joint development agreement with Warwick.

“We have been working with various types of Monster Silk™,” stated Charles Howland, President of Warwick. “We find that all of these fibers are compatible with existing yarn processing and textile formation methods. As is expected, fiber consistency is not yet at full production levels.  However, for the current stage of maturity, these silk materials already have good levels of quality and consistency.  We have been making jersey knit samples and will start weaving shortly.  These small scale trials are key to helping identify, for Kraig Labs, areas for development for upcoming fiber production trials. We are reviewing textile properties of the samples with Kraig staff and exploring the most attractive applications for this fiber.  Overall the trials are well underway and we are making good progress toward commercialization.”

“One of the biggest issues facing our Company was creating our first textile and the open question of whether genetically engineered spider silk could be successfully processed using existing textile formation methods,” said Company founder and CEO, Kim K. Thompson.  “With this successful test, and the creation of the first Monster Silk™ knits, we have established that our genetically engineered spider silk works well with existing manufacturing methods.  The creation of these knits is a huge milestone in our progress toward making genetically engineered spider silk available for industrial and consumer applications. The fact that these advanced materials process well on existing machinery will help speed up the development of advanced spider silk textiles.”

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies. The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC.

(720) 288-8495

ir@KraigLabs.com

Evaluation Team Reports Monster Silk™ Production Ramp Up is Succeeding

LANSING, Mich., May 29, 2014— Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of advanced spider silk based fibers, announced that its production evaluation team reported that the Company’s genetically engineered spider silk, Monster Silk™, production program is thriving and is successfully accommodating a recent significant increase in the scale of production.

The Company previously reported that its pilot production program’s viable silk cocoon yield rate was at approximately 30%, in late 2013.  By March, after launching the commercial production ramp up program, the yields increased to approximately 70%; more than double the output efficiency from the pilot phase.   The latest report is that with the increased scale of operations in May, the high yields appear to be holding, and possibly improving even further.

The Company believes that the high yield is a result of a combination of improved production procedures and adaptability.  The Company is ordering a further doubling of production in June.

“We always believed that our scientific model would translate very well into real world environments, but to actually see our silkworms perform at this level is inspiring.  The technology is now outperforming the infrastructural capacities, which bodes well for future product, and production, expansion,” said Company Founder and CEO, Kim K. Thompson.

“The fact that the reported yield rates are holding, or improving, has given us the confidence to authorize a doubling of the scale of production. We anticipate this next larger production run will launch in June.  We are excited and encouraged to see that our systems are holding up well as we increase the scale of Monster Silk™ production, and we are working with third parties to strengthen the infrastructure to support the increased production,” Thompson concluded.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies. The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC.

(720) 288-8495

ir@KraigLabs.com